

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with the letter dated July 25, 2008, 3. License number 45-02207-01 is amended in its entirety to read as follows:
1. Centra	
2. Alan B. Pearson Regional Cancer Center 1701 Thomson Drive Lynchburg, Virginia 24501	4. Expiration date June 30, 2016 5. Docket No. 030-03309 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1.5 curies
D. Any byproduct material permitted by 10 CFR 35.400	D. Sealed Sources (AEA Technology Model CDC.T1 [distributed by Medi-Physics, Inc.]; Bard Brachytherapy, Inc. Model STM 1251; IsoAid LLC Model IAI-125A)	D. 2 curies
E. Strontium 90 permitted by 10 CFR 35.400	E. Sealed Source (DuPont Merck Pharmaceutical Co. Model NB-1 [labeled as NEN])	E. 100 millicuries
F. Cesium 137	F. Sealed Source (Amersham Corporation Model 77302)	F. 165 millicuries

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET
SECOND CORRECTED COPY**

License Number
45-02207-01

Docket or Reference Number
030-03309

Amendment No. 74

- E. Strontium-90 for ophthalmic radiotherapy permitted by 10 CFR 35.400.
F. For storage only in an Amersham/Tech Ops Model 773 calibrator.

CONDITIONS

10. A. Licensed material may be used or stored only at the licensee's facilities located at Virginia Baptist Hospital, 3300 Rivermont Avenue, Lynchburg, Virginia.
- B. Licensed material in Items 6.A.-6.D. and 6.F. may be used or stored at the licensee's facilities located at Lynchburg General Hospital, 1901 Tate Springs Road, Lynchburg, Virginia.
- C. Licensed material limited to Iodine-125 in Item 6.D. may be used or stored at the licensee's facilities located at the Surgery Center of Lynchburg, 2401 Atherholt Road, Lynchburg, Virginia.
- D. Licensed material in Item 6B. may be used or stored at the licensee's facilities located at 900 West 3rd Street, Farmville, Virginia and at 2410 Atherholt Road, Lynchburg, Virginia.
- E. Licensed material in Items 6.C. and 6.E. may be used or stored at the licensee's facilities located at the Alan B. Pearson Regional Cancer Center, 1701 Thomson Drive, Lynchburg, Virginia.
11. The Radiation Safety Officer for this license is Brian R. Hames, M.S.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
Parham R. Fox, M.D.	35.100; 35.200; 35.300
Richard L. Newton, M.D.	35.100; 35.200; 35.300
Robert L. Green, M.D.	35.100; 35.200; 35.300
James L. Hall, Jr., M.D.	35.100; 35.200; 35.300
David B. Truitte, M.D.	35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET
SECOND CORRECTED COPY**

License Number
45-02207-01

Docket or Reference Number
030-03309

Amendment No. 74

<u>Authorized Users</u>	<u>Material and Use</u>
Timothy B. Hellewell, M.D.	35.100; 35.200
Robert L. Driskill, M.D.	35.300; 35.400
John Alfieri, M.D.	35.100; 35.200
David E. Johnsen, M.D.	35.100; 35.200; 35.300
M. Camille Alexander, M.D.	35.100; 35.200
Kevin Oliver Hicks, M.D.	35.100; 35.200; 35.300
Judith A. Perrotto, M.D.	35.100; 35.200
Jason M. Hackenbracht, M.D.	35.200
Girish Purohit, M.D.	35.200
Anita Joy Hilliard, M.D.	35.300; 35.400
Carol Joy Darrah, M.D.	35.100; 35.200
Larry H. Redmond, M.D.	35.100; 35.200; 35.300
Chad Allen Hoyt, M.D.	35.200
Daniel W. Schepens, M.D.	35.100; 35.200; Oral administration of sodium iodide I-131
Kenneth C. Hite, M.D.	35.100; 35.200; Oral administration of sodium iodide I-131; Parenteral administration of any beta emitter, or photon-emitting radionuclide with a photon energy less than 150 keV

**MATERIALS LICENSE
SUPPLEMENTARY SHEET
SECOND CORRECTED COPY**

License Number
45-02207-01

Docket or Reference Number
030-03309

Amendment No. 74

C. The following individuals are authorized medical physicists as indicated:

Authorized Medical Physicists

Material and Use

Brian R. Hames, M.S.

Strontium-90 ophthalmic sources for physical decay

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. For sealed sources not associated with 10 CFR Part 35 use, the following conditions apply:
- A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed six months or at the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State.
 - B. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.
 - C. Sealed sources need not be tested if they contain only hydrogen-3; or they contain only a radioactive gas; or the half-life of the isotope is 30 days or less; or they contain not more than 100 microcuries of beta- and/or gamma-emitting material or not more than 10 microcuries of alpha-emitting material.
 - D. Sealed sources need not be tested if they are in storage and are not being used; however, when they are removed from storage for use or transferred to another person and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.
 - E. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET
SECOND CORRECTED COPY**

License Number
45-02207-01

Docket or Reference Number
030-03309

Amendment No. 74

- F. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or by other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.
- G. Records of leak test results shall be kept in units of microcuries and shall be maintained for 5 years.
15. The licensee shall conduct a physical inventory every six months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 5 years from the date of each inventory and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.
16. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.
17. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."



**MATERIALS LICENSE
SUPPLEMENTARY SHEET
SECOND CORRECTED COPY**

License Number
45-02207-01

Docket or Reference Number
030-03309

Amendment No. 74

18. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Letter dated December 13, 2000 [ML010240356]
 - B. Letter dated October 17, 2001 [ML012950343]
 - C. Application dated November 7, 2005 [ML053220295]
 - D. Application dated January 24, 2006 [ML060310659]
 - E. Letter dated May 31, 2006 [ML061520100]
 - F. Letter dated June 14, 2006 [ML061710555]
 - G. Letter dated March 30, 2007 [ML071030153]
 - H. Letter dated December 12, 2007 [ML073530626]
 - I. Letter dated January 16, 2008 [ML080320319]
 - J. Letter dated March 3, 2008 [ML080930114]
 - K. Letter dated April 7, 2008 [ML081130234]
 - L. Letter dated May 6, 2008 [ML081420587]

For the U.S. Nuclear Regulatory Commission

Date November 5, 2008

By

Original signed by Tara L. Weidner

Tara L. Weidner
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406